

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **CHRND RABBIT PAB**

货号: S215494

产品全名: CHRND 兔多抗

基因符号 ACHRD; CMS2A; CMS3A; CMS3B; CMS3C; FCCMS; SCCMS

UNIPROT ID: Q07001 (Gene Accession - NP\_000742)

背景: The acetylcholine receptor of muscle has 5 subunits of 4 different types: 2 alpha and 1 each of beta, gamma and delta subunits. After acetylcholine binding, the receptor undergoes an extensive conformation change that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. Defects in this gene are a cause of multiple pterygium syndrome lethal type (MUPSL), congenital myasthenic syndrome slow-channel type (SCCMS), and congenital myasthenic syndrome fast-channel type (FCCMS). Several transcript variants encoding different isoforms have been found for this gene.

抗原: Synthetic peptide of human CHRND

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-50; ELISA: 5000-10000

种属反应性: Rabbit 克隆性: Rabbit Polyclonal


亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Neuroscience


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 215494(CHRND Antibody) at a dilution of 1/25(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 215494(Anti-CHRND Antibody) at dilution 1/25.



The image on the left is immunohistochemistry of paraffinembedded Human tonsil tissue using 215494(Anti-CHRND Antibody) at a dilution of 1/25.



In comparision with the IHC on the left, the same paraffin-embedded Human tonsil tissue is first treated with synthetic peptide and then with D163454(Anti-CHRND Antibody) at dilution 1/25.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010